Benzinga | May 6, 2021 07:21AM EDT

VYNE Therapeutics Q1 Adj. EPS $(0.37) Beats $(0.41) Estimate, Sales $4.12M Miss $5.31M Estimate

VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.41) by 9.76 percent. The company reported quarterly sales of $4.12 million which missed the analyst consensus estimate of $5.31 million by 22.43 percent.